When a deadly outbreak of the Ebola virus spread through the Democratic Republic of Congo in 2018, Merck’s then-unapproved vaccine was quickly deployed to help address the crisis and provide protection to hundreds of thousands of recipients. Now, four years after that epidemic ended, a new analysis offers a clearer picture on the vaccine’s real-world effectiveness.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,